Anti-N-Glycolyl-GM3 antibody 14F7

Drug Profile

Anti-N-Glycolyl-GM3 antibody 14F7

Alternative Names: 14F7; Humanised monoclonal antibody 14F7; Monoclonal antibody 14F7

Latest Information Update: 26 Oct 2016

Price : $50

At a glance

  • Originator Center of Molecular Immunology
  • Class Antineoplastics; Diagnostic agents; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 08 Sep 2016 The drug is still in preclinical development for Solid tumours (diagnosis) in Cuba (unspecified route)
  • 29 Aug 2016 Center of Molecular Immunology plans a phase I trial in solid tumours (Late-stage disease) in Cuba (RPCEC00000204)
  • 28 Mar 2003 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top